-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

AML M&Ms: How to Integrate Mutations and MRD Data

Program: Education Program
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality), Genomics, Diseases, Myeloid Malignancies, Biological Processes, Measurable Residual Disease
Saturday, December 7, 2024: 9:30 AM-10:45 AM
Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)

Description:
The genomic heterogeneity of AML, the clinical variability of patients and patient outcomes to various therapies, and the underlying awareness and evaluation of clonal evolution mandates an integrated approach to AML risk assessment and treatment decision-making.   This session will focus on the clinical management of AML using a comprehensive evaluation including both genetic characterization and MRD-based response assessments during therapy, to optimize the clinical outcomes of patients with AML.

Dr. Jerald Radich will examine the role of MRD as an indicator of treatment response, and help answer the question of why some patients with persistent MRD do not relapse, while others without detectable MRD may still relapse nonetheless.  He will explore how to best use MRD to optimize patient care, and explore how the mutational landscape of AML at diagnosis and during therapy can help to explain not only the clinical utility of MRD but also key features of leukemia biology.

Dr. Michael Heuser will discuss the prognostic impact of MRD status in different genetic risk groups and provide an overview on the available MRD technologies to monitor treatment response in transplant-eligible patients with AML. He will help to unravel the complex matrix of MRD and mutational dependencies for practical clinical application and management decisions in patients with AML.

Dr. Courtney DiNardo will summarize the current treatment landscape of AML in patients ineligible for transplant, and focus on the importance of a comprehensive genomic assessment to identify optimal treatment strategies both at diagnosis and relapse.  She will also highlight the role of MRD assessments and review the role of MRD measurements to guide treatment decisions in patients receiving non-intensive therapies.

Chair:
Courtney D. DiNardo, MD, MSc, MD Anderson Cancer Center
Disclosures:
DiNardo: AstraZeneca: Honoraria; GSK: Consultancy, Honoraria; Servier: Consultancy, Honoraria, Other: meetingsupport, Research Funding; Genetech: Honoraria; Riegel: Honoraria; Notable Labs: Honoraria; Immunogen: Honoraria; Schrodinger: Consultancy, Honoraria; Stemline: Consultancy; ImmuneOnc: Research Funding; Loxo: Research Funding; Rigel: Research Funding; Amgen: Consultancy; Jazz: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Cleave: Research Funding; BMS: Consultancy, Honoraria, Research Funding; Astex: Research Funding; GenMab: Consultancy, Honoraria, Other: data safety board; Gilead: Consultancy; Foghorn: Research Funding; Abbvie: Consultancy, Honoraria, Research Funding.
The genomic heterogeneity of AML, the clinical variability of patients and patient outcomes to various therapies, and the underlying awareness and evaluation of clonal evolution mandates an integrated approach to AML risk assessment and treatment decision-making.   This session will focus on the clinical management of AML using a comprehensive evaluation including both genetic characterization and MRD-based response assessments during therapy, to optimize the clinical outcomes of patients with AML.

Dr. Jerald Radich will examine the role of MRD as an indicator of treatment response, and help answer the question of why some patients with persistent MRD do not relapse, while others without detectable MRD may still relapse nonetheless.  He will explore how to best use MRD to optimize patient care, and explore how the mutational landscape of AML at diagnosis and during therapy can help to explain not only the clinical utility of MRD but also key features of leukemia biology.

Dr. Michael Heuser will discuss the prognostic impact of MRD status in different genetic risk groups and provide an overview on the available MRD technologies to monitor treatment response in transplant-eligible patients with AML. He will help to unravel the complex matrix of MRD and mutational dependencies for practical clinical application and management decisions in patients with AML.

Dr. Courtney DiNardo will summarize the current treatment landscape of AML in patients ineligible for transplant, and focus on the importance of a comprehensive genomic assessment to identify optimal treatment strategies both at diagnosis and relapse.  She will also highlight the role of MRD assessments and review the role of MRD measurements to guide treatment decisions in patients receiving non-intensive therapies.

Jerald P. Radich, MD

Department of Pathology, University of Washington School of Medicine, Seattle, WA

Michael Heuser, MD

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

See more of: Education Program